<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200926048842N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-08</date_registration>
      <primary_sponsor>Semnan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of rose and lavender aromatherapy on pain intensity and treatment of colorectal cancer under chemotherapy</public_title>
      <acronym></acronym>
      <scientific_title>A comparative study of the effects of rose water aromatherapy and lavender aromatherapy on the intensity of pain and fatigue of colorectal cancer patients undergoing chemotherapy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71028</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Supportive, Randomization description: Sampling will be done by the available method. Every patient with colorectal cancer referring to Kausar (Semnan city) and Bahar (Shahroud city) hospitals who meets the inclusion criteria should be included in the study. Then the selected patients are cross-divided into two groups (A, B). In this way, first, envelopes with group names are prepared for the total number of study subjects and randomly arranged and selected by reference and selection of individuals, one of the cards will be identified, which will determine the individual's group. Was. According to random sampling, the research samples will have an equal chance to be selected in two groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Colorectal cancer.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: At first, the demographic information form, and visual pain level (VAS) and fatigue level (MFI) questionnaires will be completed for patients in group A. Then these people will be subjected to inhalation aromatherapy intervention with rose essence in separate rooms individually. The interventionist was present in the chemotherapy department of the mentioned hospitals, and for the participants in this group, during a session of 4:30 hours from the moment of starting the chemotherapy, 5 drops of the essential oil of the rose flower provided by Gulabgiri Kashan Company with He will pour the prepared 1.5% concentration on a piece of cotton and place it on the collar of the patient's clothes at a distance of about 20 cm from the nose. The cotton piece remains in place for 4:30 hours during chemotherapy. Again, the level of pain and fatigue of the patients will be completed based on the mentioned questionnaires in the period of thirty minutes, one hour and three hours from the start of the aromatherapy intervention for this group of patients. Then the intervention is washed out for a week so that the effects of rose water aroma therapy in this group disappear. After that, the visual pain level (VAS) and fatigue level (MFI) questionnaires will be completed again for group A patients. In the following, these people under the intervention of inhalation aroma therapy with lavender essential oil with a concentration of 1.5% prepared by Barij Essential Oil Company of Kashan will pour 5 drops of the above scent on a piece of cotton and put it on the collar of the patient's clothes with about 20 cm meters away from the nose. The cotton piece remains in place for 4:30 hours during chemotherapy. Again, the level of pain and fatigue of the patients will be completed based on the mentioned questionnaires in the period of thirty minutes, one hour and three hours from the start of the aromatherapy intervention for this group of patients. Intervention 2: The second intervention group: At first, the demographic information form, and visual pain level (VAS) and fatigue level (MFI) questionnaires will be completed for patients in group B. Then these people will be subjected to inhalation aromatherapy intervention with lavender essential oil in separate rooms individually. The interventionist was present in the chemotherapy department of the mentioned hospitals, and for the participants in this group, during a session of 4:30 hours from the moment of the start of chemotherapy, 5 drops of lavender scent, which was provided by Barij Essan Company of Kashan with He will pour the prepared 1.5% concentration on a piece of cotton and place it on the collar of the patient's clothes at a distance of about 20 cm from the nose. The cotton piece remains in place for 4:30 hours during chemotherapy. Again, the level of pain and fatigue of the patients will be completed based on the mentioned questionnaires in the period of thirty minutes, one hour and three hours from the start of the aromatherapy intervention for this group of patients. Then the intervention is washed out for a week so that the effects of lavender aromatherapy in this group disappear. After that, the visual pain level (VAS) and fatigue level (MFI) questionnaires will be completed again for group B patients. In the following, these people under the intervention of inhalation aroma therapy with rose essence with a concentration of 1.5%, prepared by Gulab Giri Kashan Company, will pour 5 drops of the above scent on a piece of cotton and put it on the collar of the patient's clothes with about 20 cm meters away from the nose. The cotton piece remains in place for 4:30 hours during chemotherapy. Again, the level of pain and fatigue of the patients will be completed based on the mentioned questionnaires in the period of thirty minutes, one hour and three hours from the start of the aromatherapy intervention for this group of patients.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sajad Salehipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 19, Alley 12, Lebanon Martyrs Street, Tehran Avenue</address>
        <city>Shahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3619676483</zip>
        <telephone>+98 23 3237 3188</telephone>
        <email>ssn.shahroud@yahoo.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sajad Salehipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 19, Alley 12, Lebanon Martyrs Street, Tehran Avenue</address>
        <city>Shahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3619676483</zip>
        <telephone>+98 23 3237 3188</telephone>
        <email>ssn.shahroud@yahoo.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Insensitivity to plants and their extracts according to the person's previous history
Colorectal cancer has been definitively diagnosed by a hematologist and oncologist.
Undergoing the first cycle of chemotherapy up to a maximum of the fifth cycle of chemotherapy
Having a pain intensity score of at least 3 based on the questionnaire (VAS)
No smoking, drugs and alcohol
Not suffering from other known chronic diseases such as heart-pulmonary diseases, blood pressure and diabetes
Not using perfume or cologne before or during the intervention
Not having an olfactory disorder and also having a cold and nasal congestion that should affect the sense of smell
Absence of mental disorders
Not receiving natural painkillers 3 hours before the start or during the intervention
Having a history of surgery in less than 3 months
Having hemoglobin of at least 8gr/dl</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Use of other pain relief methods during the study
Refusal to continue participating in the study
The patient's lack of awareness colorectal cancer
Decreased level of alertness while studying
Occurrence of skin and eye allergies during study
The occurrence of severe physical complications caused by the disease
death of the patient
suffering from diseases characterized by fatigue (multiple sclerosis, fibromyalgia, AIDS, joint rheumatism)
Presence of perceptual disorders related to smell (olfactory hallucinations)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C19</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of rectosigmoid junction</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: At first, the demographic information form, and visual pain level (VAS) and fatigue level (MFI) questionnaires will be completed for patients in group A. Then these people will be subjected to inhalation aromatherapy intervention with rose essence in separate rooms individually. The interventionist was present in the chemotherapy department of the mentioned hospitals, and for the participants in this group, during a session of 4:30 hours from the moment of starting the chemotherapy, 5 drops of the essential oil of the rose flower provided by Gulabgiri Kashan Company with He will pour the prepared 1.5% concentration on a piece of cotton and place it on the collar of the patient's clothes at a distance of about 20 cm from the nose. The cotton piece remains in place for 4:30 hours during chemotherapy. Again, the level of pain and fatigue of the patients will be completed based on the mentioned questionnaires in the period of thirty minutes, one hour and three hours from the start of the aromatherapy intervention for this group of patients. Then the intervention is washed out for a week so that the effects of rose water aroma therapy in this group disappear. After that, the visual pain level (VAS) and fatigue level (MFI) questionnaires will be completed again for group A patients. In the following, these people under the intervention of inhalation aroma therapy with lavender essential oil with a concentration of 1.5% prepared by Barij Essential Oil Company of Kashan will pour 5 drops of the above scent on a piece of cotton and put it on the collar of the patient's clothes with about 20 cm meters away from the nose. The cotton piece remains in place for 4:30 hours during chemotherapy. Again, the level of pain and fatigue of the patients will be completed based on the mentioned questionnaires in the period of thirty minutes, one hour and three hours from the start of the aromatherapy intervention for this group of patients.</i_keyword>
      <i_keyword>The second intervention group: At first, the demographic information form, and visual pain level (VAS) and fatigue level (MFI) questionnaires will be completed for patients in group B. Then these people will be subjected to inhalation aromatherapy intervention with lavender essential oil in separate rooms individually. The interventionist was present in the chemotherapy department of the mentioned hospitals, and for the participants in this group, during a session of 4:30 hours from the moment of the start of chemotherapy, 5 drops of lavender scent, which was provided by Barij Essan Company of Kashan with He will pour the prepared 1.5% concentration on a piece of cotton and place it on the collar of the patient's clothes at a distance of about 20 cm from the nose. The cotton piece remains in place for 4:30 hours during chemotherapy. Again, the level of pain and fatigue of the patients will be completed based on the mentioned questionnaires in the period of thirty minutes, one hour and three hours from the start of the aromatherapy intervention for this group of patients. Then the intervention is washed out for a week so that the effects of lavender aromatherapy in this group disappear. After that, the visual pain level (VAS) and fatigue level (MFI) questionnaires will be completed again for group B patients. In the following, these people under the intervention of inhalation aroma therapy with rose essence with a concentration of 1.5%, prepared by Gulab Giri Kashan Company, will pour 5 drops of the above scent on a piece of cotton and put it on the collar of the patient's clothes with about 20 cm meters away from the nose. The cotton piece remains in place for 4:30 hours during chemotherapy. Again, the level of pain and fatigue of the patients will be completed based on the mentioned questionnaires in the period of thirty minutes, one hour and three hours from the start of the aromatherapy intervention for this group of patients.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: It is before the start of the intervention and thirty minutes and one hour and three hours after the intervention. Method of measurement: The visual scale for measuring pain intensity is a 10 cm ruler, on the left end of which the word no pain is written and on the right end the word the most severe state of pain is written. According to the amount of pain in the last 48 hours, the person puts a mark on the continuum; Then the amount of pain is measured by the researcher using the visual pain intensity measurement scale (VAS) which is standardized for pain measurement. The visual scale for measuring pain intensity from zero to ten is divided as follows: 0-1: (no pain) / 2-3: (little pain) / 4-5: (extreme pain) / 6-7: (pain) very bad)/ 8-9: (maximum pain) and 10 (unbearable pain).</prim_outcome>
      <prim_outcome>Fatigue rate. Timepoint: It is before the start of the intervention and thirty minutes and one hour and three hours after the intervention. Method of measurement: The questionnaire (MFI) consists of 20 items and 5 subscales of general fatigue (4 questions), physical fatigue (4 questions), decreased activity (4 questions), decreased motivation (4 questions) and mental fatigue (4 questions), which It is used to measure fatigue. The scoring of the questionnaire is on a 5-option Likert scale from 1 = yes, completely true to 5 = no, completely false. Questions number 2, 5, 9, 10, 13, 14, 16, 17, 18, 19 are graded in reverse order and are graded as 5 completely correct to 1 completely incorrect. To get the overall score of the questionnaire, the scores of all items are added together. The total score of each field is 4-20 and the total score of fatigue determined by the sum of the scores of the fields can be between 20-100. A higher score indicates greater fatigue.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Semnan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-26</approval_date>
        <contact_name>Ethics committee of Semnan University of Medical Sciences</contact_name>
        <contact_address>Headquarters of Semnan University of Medical Sciences and Health Services, Basij Blvd Semnan Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
